Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
oleh: Sunit Das, Arjun Sahgal, James R. Perry
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2020-01-01 |
Deskripsi
Subjek
glioblastoma; chemotherapy; temozolomide; lomustine (CCNU); radiation therapy